INTS net incomeQ3 2026-$3.54M
INTS net income was -$3.54M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$2.67M a year earlier. For the full fiscal 2025 it was -$11.61M, compared with -$16.27M in fiscal 2024.
Intensity Therapeutics Inc. (INTS) financials
For the twelve months ended Sep 30, 2026, Intensity Therapeutics Inc. reported -$12.04M of net income.
- Net income, TTM
- -$12.04M
- Cash
- $8.49M
- Market cap
- $10.1M
FY2022FY2025
INTS revenue and earnings growth
INTS EPSQ3 2026-$1.09
INTS diluted EPS was -$1.09 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$8.56.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Research and development | $6.79M | $10.50M | $4.79M | $5.13M |
| Selling, general and admin | $5.19M | $6.09M | $3.53M | $2.42M |
| Operating income | -$11.97M | -$16.59M | -$8.32M | -$7.55M |
| Interest expense | - | $0 | $305.0K | $82.0K |
| Income tax | $0 | $0 | $0 | $0 |
| Net income | -$11.61M | -$16.27M | -$10.54M | -$7.58M |
| EPS, basic | -$8.56 | -$29.24 | -$34.50 | -$55.50 |
| EPS, diluted | -$8.56 | -$29.24 | -$34.50 | -$55.50 |
| Diluted shares | 1.4M | 556,279 | 344,652.96 | 136,404.12 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $11.92M | $2.59M | $8.56M | $1.31M |
| Current assets | $12.71M | $3.36M | $15.46M | $1.45M |
| Total assets | $14.10M | $4.78M | $17.30M | $1.76M |
| Current liabilities | $2.15M | $1.75M | $3.96M | $6.82M |
| Total liabilities | $2.23M | $1.86M | $4.13M | $6.86M |
| Shareholders' equity | $11.88M | $2.92M | $13.16M | -$15.10M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$9.23M | -$15.22M | -$7.21M | -$5.48M |
| Investing cash flow | $0 | $6.35M | -$6.02M | $0 |
| Financing cash flow | $18.56M | $2.90M | $20.47M | $2.25M |
| Stock-based compensation | $2.00M | $3.07M | $1.40M | $1.17M |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $2.43M | $1.83M | $1.20M | $1.50M | $1.55M | $1.54M | $2.19M | $1.97M | $2.15M | $3.56M | $2.81M | $1.80M |
| Selling, general and admin | $1.19M | $1.25M | $1.33M | $1.64M | $1.18M | $1.16M | $1.21M | $1.24M | $1.42M | $1.51M | $1.93M | $1.55M |
| Operating income | -$3.62M | -$3.08M | -$2.53M | -$3.14M | -$2.73M | -$2.71M | -$3.39M | -$3.20M | -$3.57M | -$5.07M | -$4.74M | -$3.35M |
| Interest expense | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $0 |
| Net income | -$3.54M | -$3.01M | -$2.43M | -$3.05M | -$2.67M | -$2.54M | -$3.35M | -$3.18M | -$3.51M | -$4.97M | -$4.60M | -$3.17M |
| EPS, basic | -$1.09 | -$1.11 | -$0.96 | - | -$1.55 | -$3.36 | -$5.51 | -$5.49 | -$6.25 | -$9.00 | -$8.50 | - |
| EPS, diluted | -$1.09 | -$1.11 | -$0.96 | - | -$1.55 | -$3.36 | -$5.51 | -$5.49 | -$6.25 | -$9.00 | -$8.50 | - |
| Diluted shares | 3.3M | 2.7M | 2.5M | - | 1.7M | 754,725 | 606,928 | - | 552,186.04 | 548,486.08 | 548,379.48 | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.49M | $9.53M | $10.24M | $11.92M | $7.07M | $2.22M | $929.0K | $2.59M | $2.78M | $3.24M | $7.46M | $8.56M |
| Receivables | $41.3K | - | - | - | - | - | - | - | - | - | - | - |
| Current assets | $9.50M | $11.23M | $10.91M | $12.71M | $8.19M | $3.04M | $1.65M | $3.36M | $3.79M | $7.44M | $11.17M | $15.46M |
| Total assets | $10.29M | $11.52M | $12.29M | $14.10M | $9.59M | $4.44M | $3.06M | $4.78M | $5.21M | $8.67M | $12.41M | $17.30M |
| Current liabilities | $2.58M | $2.25M | $2.24M | $2.15M | $2.28M | $2.16M | $2.63M | $1.75M | $2.32M | $3.20M | $2.52M | $3.96M |
| Total liabilities | $2.63M | $2.31M | $2.31M | $2.23M | $2.36M | $2.26M | $2.73M | $1.86M | $2.43M | $3.33M | $2.69M | $4.13M |
| Shareholders' equity | $7.65M | $9.21M | $9.98M | $11.88M | $7.22M | $2.18M | $334.0K | $2.92M | $2.78M | $5.34M | $9.72M | $13.16M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.50M | -$2.34M | -$1.83M | -$2.40M | -$2.39M | -$2.46M | -$1.99M | -$2.67M | -$3.97M | -$4.21M | -$4.37M | -$946.0K |
| Investing cash flow | - | - | - | $0 | $0 | $0 | $0 | $0 | $3.10M | -$6.0K | $3.26M | $2.82M |
| Financing cash flow | $1.47M | $1.62M | $150.0K | $7.25M | $7.24M | $3.74M | $328.0K | $2.48M | $413.0K | $3.0K | $8.0K | -$13.0K |
| Stock-based compensation | $517.0K | $387.0K | $387.0K | $450.0K | $471.0K | $644.0K | $435.0K | $844.0K | $483.0K | $591.0K | $1.16M | $423.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.68 | 5.00 | 4.86 | 5.92 | 3.60 | 1.40 | 0.63 | 1.92 | 1.63 | 2.32 | 4.43 | 3.91 |
Source: XBRL data Intensity Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Mar 27, 2026.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
INTS peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| INTS | - | - | -$12.04M | - | $10.1M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $248.84B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $207.84B |
| MRNA | $2.23B | -27.6% | -$3.15B | -141.4% | $96.40B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $55.53B |
| RVMD | $0 | - | -$1.13B | - | $38.08B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $36.06B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.57B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $16.77B |
INTS FAQ
4 questionsIs INTS profitable?
No. Intensity Therapeutics Inc. reported a net loss of $12.04M for the twelve months ended Sep 30, 2026.How much cash and debt does INTS have?
Intensity Therapeutics Inc. reported $8.49M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did INTS last report financial results?
The latest statements here come from Intensity Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this INTS financial data come from?
Quantisnow builds these statements from the structured XBRL data Intensity Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.